<DOC>
	<DOCNO>NCT00621049</DOCNO>
	<brief_summary>Multicenter randomize phase II trial examine safety efficacy carboplatin , docetaxel , bevacizumab follow maintenance bevacizumab erlotinib patient completely resect stage IB , II , select III NSCLC .</brief_summary>
	<brief_title>Carboplatin , Docetaxel , Bevacizumab , Erlotinib Versus Chemotherapy Alone Resected NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Patients must histologicallyconfirmed nonsmall cell lung cancer ( adenocarcinoma , squamous , large cell undifferentiated ) . Mixed small cell nonsmall histology exclude . 2 . Patients completely resect ( R0 ) stage IB , II , select III NSCLC . The following stage eligible : IB T2 N0 IIA T1 N1 IIB T2 N1 IIB T3 N0 IIIA T3 N1 Bronchioalveolar carcinoma present single , solitary discrete nodule mass may include Patients determine N2 disease , apparent radiologically preoperatively ( completely resect ) include . 3 . Complete surgical resection define appropriate pulmonary parenchymal resection include lobectomy , bilobectomy , sleeve lobectomy , pneumonectomy histologically confirm negative bronchial margin . Patients treat segmentectomy wedge resection eligible study . Additionally patient must either mediastinal node dissection least , sample 2 mediastinal nodal station ( level 4,7 , 9 rightsided tumor , level 5,6,7 , 9 leftsided tumor suggest . ) 4 . No evidence metastatic disease 5 . ANC &gt; = 1500 , platelet &gt; = 100,000 hemoglobin &gt; = 10.0 . 6 . Total bilirubin &lt; = ULN . AST ALT alkaline phosphatase must WNL 7 . Serum creatinine &lt; = 1.5mg/dl ( If great 1.5 , creatinine clearance , calculate accord CockroftGault formula , must &gt; = 50ml/min ) . 8 . Patients may previous chemotherapy , radiation therapy , angiogenesis inhibitor , tyrosine kinase inhibitor nonsmall cell lung cancer . 9 . Patients must able understand nature study give write informed consent . 10 . Age &gt; = 18 year 11 . Ability start treatment 8 12 week follow surgery . 12 . Ability take oral medication . 1 . Patients preoperative radiologic evidence N2 disease either PET CT scan ( i.e . radiological evidence metastasis ipsilateral mediastinal subcarinal node ) confirm N2 disease histologically exclude . PLEASE SEE EXCEPTION section 3.1.2 protocol 2 . Mixed small cell nonsmall cell histology 3 . Pulmonary carcinoid tumor 4 . Positive bronchial margin 5 . History prior malignancy within 5 year exception skin cancer cervical carcinoma situ . 6 . Women pregnant ( positive pregnancy test ) breastfeeding . Subjects childbearing potential partner childbearing potential ( woman men ) must use effective birth control measure treatment . 7 . Treatment nonapproved investigational drug within 30 day day 1 trial treatment . 8 . Patients seizures controlled standard medical therapy . 9 . Patients active infection require parenteral antibiotic 10 . Patients major surgical procedure , open biopsy , significant traumatic injury within 8 week begin study treatment anticipation need major surgical procedure course study 11 . Fine needle aspiration , core biopsy minor surgical procedure ( exclude placement vascular access device ) within 7 day begin study treatment . 12 . Patients receive thrombolytic therapy within 10 day start study treatment also ineligible . Patients may receive prophylactic anticoagulation therapy , 1 mg coumadin daily port clot prophylaxis . 13 . Patients proteinuria screen demonstrate either : Urine protein creatinine ( UPC ) ratio &gt; = 1.0 screening OR Urine dipstick proteinuria &gt; = 2+ ( patient discover &gt; = 2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate &gt; = 1 g protein 24hours eligible ) . 14 . Patients serious nonhealing wound , ulcer , bone fracture . 15 . Patients evidence bleed diathesis coagulopathy . 16 . Patients history hemoptysis define bright red blood Â½ teaspoon per episode ) within 8 week prior study treatment . 17 . History myocardial infarction unstable angina within 6 month begin study treatment . 18 . Inadequately control hypertension ( define systolic blood pressure &gt; 150 /or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) . 19 . New York Heart Association ( NYHA ) grade II great CHF . 20 . Serious cardiac arrhythmia require medication . 21 . Symptomatic peripheral vascular disease . 22 . History stroke transient ischemic attack within 6 month prior begin bevacizumab . 23 . Any prior history hypertensive crisis hypertensive encephalopathy . 24 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior begin study treatment . 25 . ECOG Performance status &gt; 1 . 26 . Peripheral neuropathy &gt; grade 1 . 27 . Known hypersensitivity component study drug include platinum drug formulate polysorbate 80 . 28 . Impaired oral absorption . 29 . Inability comply study and/or followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Resected</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Erlotinib</keyword>
</DOC>